The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

Pulmonary Disease, Chronic Obstructive Clinical Trial

Official title:

A Randomized, Double-blind, Double-dummy, Active-controlled, Multi-center, Parallel Group Study to Show the Superiority in Lung Function of 12 Weeks Once Daily Treatment With Orally Inhaled Tiotropium+Olodaterol Fixed Dose Combination Delivered by the Respimat® Inhaler vs. 12 Weeks Twice Daily Treatment With Fluticasone Propionate+Salmeterol Fixed Dose Combination Delivered by the Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD) [ENERGITO® 2]

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03240575
• Other study ID #: 1237-0063
• Status: Completed
• Phase: Phase 4
• Start date: August 14, 2017
• Est. completion date: May 6, 2019

Study information

• Verified date: April 2020
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of the trial is to show superiority in lung function of once daily (2 inhalations) treatment with orally inhaled tiotropium+olodaterol fixed dose combination to twice daily (one inhalation) treatment with fluticasone propionate+salmeterol fixed dose combination over 12 weeks in patients with Chronic Obstructive Pulmonary Disease (COPD).

A Digital Health (DH) exploratory study has been integrated into the main study as a site specific study. The DH exploratory study will be performed at a single site; the site is also participating in the main study. The DH exploratory study site will enter (randomize) approximately 20 patients (subjects) (in addition to the patients to be enrolled in the main study at this site). The patients enrolled in the DH exploratory study are not considered to be part of the main study (i.e. data collected in the DH exploratory study will be analyzed separately from the data collected in the main study).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 302
• Est. completion date: May 6, 2019
• Est. primary completion date: April 8, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• All patients must sign an informed consent consistent with FDA regulations prior to participation in the trial, which includes medication washout and restrictions.

• All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria:

-- Patients with a post-bronchodilator 30% = Forced Expiratory Volume in one second (FEV1) <80% of predicted normal (European Coal and Steel Community( ECSC)); and a post-bronchodilator FEV1/Forced Vital Capacity (FVC) <70% at Visit 1

• Male or female patients, 40 years of age or older.

• Patients must be current or ex-smokers with a smoking history of more than 10 pack years. Patients who have never smoked cigarettes must be excluded.

• Patients must be able to perform, according to investigator's judgment, all trial related procedures including:

• Technically acceptable pulmonary function tests (spirometry)

• Completion of study questionnaires

• Patients must be able to inhale medication in a competent manner (in the opinion of the investigator) from the Respimat® and Diskus® inhalers and from a metered dose inhaler (MDI).

Exclusion Criteria:

• Patients with a significant disease other than Chronic Obstructive Pulmonary Disease (COPD); a significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the study, (ii) influence the results of the study, or (iii) cause concern regarding the patient's ability to participate in the study.

• Patients who have had a COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or intravenous) or hospitalization in the last 3 months prior to Visit 1 and/or between Visit 1 and Visit 2.

• Patients with a history of asthma. For patients with allergic rhinitis or atopy, source documentation is required to verify that the patient does not have asthma. If a patient has a total blood eosinophil count = 600/mm3, source documentation is required to verify that the increased eosinophil count is related to a nonasthmatic condition.

Patients with any of the following conditions:

• A diagnosis of thyrotoxicosis (due to the known class side effect profile of ß2-agonists).

• A diagnosis of paroxysmal tachycardia (>100 beats per minute) (due to the known class side effect profile of ß2-agonists).

• A history of myocardial infarction within 1 year of screening visit (Visit 1).

• Unstable or life-threatening cardiac arrhythmia.

• Hospitalization for heart failure within the past year.

• Known active tuberculosis.

• A malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed).

• A history of life-threatening pulmonary obstruction.

• A history of cystic fibrosis.

• Clinically evident bronchiectasis.

• A history of significant alcohol or drug abuse.

• Patients who have undergone thoracotomy with pulmonary resection (patients with a history of thoracotomy for other reasons should be evaluated as per the first exclusion criterion).

• Patients being treated with oral or patch ß-adrenergics.

• Patients being treated with oral corticosteroid medication within 6 weeks prior to Visit 1.

• Patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy during clinic visits.

• Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit (Visit 1) or patients who are currently in a pulmonary rehabilitation program.

• Patients who have taken an investigational drug within one month, six half-lives or within the wash out period (whichever is greater) prior to screening visit (Visit 1).

• Patients with known hypersensitivity to ß-adrenergic drugs, BAC, EDTA, or any other component of the Respimat® inhalation solution. In addition, patients with known hypersensitivity to Lactose monohydrate (which contains milk proteins).

• Pregnant or nursing women.

• Women of childbearing potential not using a method of birth control classified at least as "acceptable". Female patients will be considered to be of childbearing potential unless surgically sterilized by hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or post-menopausal (defined as no menses for 12 months without an alternative medical cause). Tubal ligation is NOT a method of permanent sterilisation.

• Patients who have previously been randomized in this study or are currently participating in another study.

• Patients who are unable to comply with pulmonary medication restrictions prior to randomization.

Related Conditions & MeSH terms

• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• Tiotropium
Fixed Dose Combination
• Olodaterol
Fixed Dose Combination
• Fluticasone propionate
Fixed Dose Combination
• Salmeterol
Fixed Dose Combination

Locations

Country	Name	City	State
United States	Johns Hopkins Hospital	Baltimore	Maryland
United States	IMMUNOe Research Centers	Centennial	Colorado
United States	Lowcountry Lung and Critical Care	Charleston	South Carolina
United States	Bernstein Clinical Rsrch Ctr	Cincinnati	Ohio
United States	Clinical Research of West Florida, Inc.	Clearwater	Florida
United States	Aventiv Research Inc.	Columbus	Ohio
United States	Aventiv Research Inc.	Dublin	Ohio
United States	Duluth Biomedical Research	Duluth	Georgia
United States	VitaLink Research - Easley	Easley	South Carolina
United States	Minnesota Lung Center and Sleep Institute	Edina	Minnesota
United States	OK Clinical Research, LLC	Edmond	Oklahoma
United States	Pulmonary Rsrch Inst of SE MI	Farmington Hills	Michigan
United States	Clinical Trial Connection	Flagstaff	Arizona
United States	California Research Medical Group, Inc.	Fullerton	California
United States	VitaLink Research -Gaffney	Gaffney	South Carolina
United States	Gastonia Pharmaceutical Research, LLC	Gastonia	North Carolina
United States	VitaLink Research	Greenville	South Carolina
United States	Hendersonville Pharmaceutical Research	Hendersonville	North Carolina
United States	Centex Studies, Inc.	Houston	Texas
United States	Allergy and Asthma Specialists Medical Group	Huntington Beach	California
United States	Jasper Summit Research, LLC	Jasper	Alabama
United States	DC Pulmonary Medicine	Marietta	Georgia
United States	Clinical Research Institute Inc	Minneapolis	Minnesota
United States	Morgantown Pulmonary ClinRsrch	Morgantown	West Virginia
United States	Northwell Health	New Hyde Park	New York
United States	New Orleans Center for Clinical Research	New Orleans	Louisiana
United States	California Medical Research Associates Inc.	Northridge	California
United States	IPS Research Company	Oklahoma City	Oklahoma
United States	Bioclinica Research	Orlando	Florida
United States	IMIC, Inc	Palmetto Bay	Florida
United States	Arcuri Clinical Research, LLC	Philadelphia	Pennsylvania
United States	Advanced Clinical Research Associates	Plano	Texas
United States	North Carolina Clinical Research	Raleigh	North Carolina
United States	Pulmonary Associates of Richmond, Inc.	Richmond	Virginia
United States	Pulmonary Associates of Richmond, Inc.	Richmond	Virginia
United States	Vita Link Research- Rock Hill	Rock Hill	South Carolina
United States	The Clinical Research Center, LLC	Saint Louis	Missouri
United States	Sherman Clinical Research	Sherman	Texas
United States	South Carolina Pharma Rsrch	Spartanburg	South Carolina
United States	Spartanburg Medical Research	Spartanburg	South Carolina
United States	MultiCare Institute for Research and Innovation	Tacoma	Washington
United States	Clinical Research of West Florida, Inc.	Tampa	Florida
United States	DM Clinical Research	Tomball	Texas
United States	Southeastern Research Center	Winston-Salem	North Carolina
United States	Minnesota Lung Center	Woodbury	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 24 Hours (AUC0-24) Response (Change From Baseline) [L] After 12 Weeks of Treatment	Forced Expiratory Volume in one second (FEV1) Area under the Curve from 0 to 24 hours (AUC0-24) response (change from baseline) [L] after 12 weeks of treatment. FEV1 AUC0-24 was calculated as the area under the FEV1-time curve from 0-24 hours post-dose using the trapezoidal rule, divided by the duration (24 hours) and reported in liters. FEV1 AUC0-24 response (change from baseline) was defined as FEV1 AUC0-24 mius baseline FEV1.	1 hours (h) and 10 minutes (min) before first dose at day1 of weeks 1 for baseline.10 min before and 30 min, 1 h, 2h, 3h, 4h, 6h, 8h, 10h, 11h 50min, 12h 30 min, 13h, 14h, 22h, 23h, and 24h post morning dose at week 12.
Secondary	Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 12 Hours (AUC0-12) Response (Change From Baseline) [L] After 12 Weeks of Treatment	Forced Expiratory Volume in one second (FEV1) Area under the Curve from 0 to 12 hours (AUC0-12) response (change from baseline) [L] after 12 weeks of treatment.; FEV1 AUC0-12 was calculated as the area under the FEV1-time curve from 0-12 hours post-dose using the trapezoidal rule, divided by the duration (12 hours) and reported in liters. FEV1 AUC0-12 response (change from baseline) was defined as FEV1 AUC0-12 minus baseline FEV1.	1 hours (h) and 10 minutes (min) before first dose at day1 of weeks 1 for baseline. 10 min before and 30 min, 1 h, 2h, 3h, 4h, 6h, 8h, 10h, 11h 50min post morning dose at week 12.
Secondary	Trough Forced Expiratory Volume in One Second (FEV1) Response (Change From Baseline) [L] After 12 Weeks Treatment	Trough Forced Expiratory Volume in one second (FEV1) response (change from baseline) [L] after 12 weeks treatment. Trough FEV1 was defined as the mean of the FEV1 value measured at 23 hours and at 24 hours after the trial medication administration. Through FEV1 response (change from baseline) was defined as trough FEV1 minus baseline FEV1.	At 23 h and 24 h post dose at baseline and at 23h and 24 h post dose at week 12.
Secondary	Peak 0-3 Hours Forced Expiratory Volume in One Second (FEV1) Response (Change From Baseline) [L] After 12 Weeks Treatment	Peak 0-3 hours Forced Expiratory Volume in one second (FEV1) response (change from baseline) [L] after 12 weeks treatment. Peak 0-3h was defined as the maximum value measured within the first three hours post doing.	30 minutes, 1 h, 2h and 3h post dose at baseline and week 12.

External Links

•   Related Info